PMLiVE5d
J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study
Rybrevant (amivantamab-vmjw) combination has demonstrated a positive overall survival trend in adults with lung cancer, ...
PMLiVE4d
Merck presents positive phase 3 results for Keytruda regimen in early-stage breast cancer
Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...
PMLiVE10d
Sanofi, RadioMedix and Orano Med partner to develop rare cancer therapy in deal worth €320m
Sanofi, RadioMedix and Orano Med have entered into an exclusive licensing agreement worth €320m to develop a next-generation ...
PMLiVE13d
GSK shares positive phase 3 results for long-acting biologic in severe asthma
GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...
PMLiVE6d
Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types
Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...
PMLiVE7d
Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...
PMLiVE11d
Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...
PMLiVE12d
Gilead and AI-focused Genesis partner to develop small molecule therapies
Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...
PMLiVE12d
Merck and Daiichi Sankyo’s ADC candidate ifinatamab deruxtecan shows promise in SCLC
Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...
PMLiVE10d
The challenge of environmental management in the pharma industry
The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...
PMLiVE13d
Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study
Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...
PMLiVE14d
FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy
The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...